Azeem Sharda
Impact in
- Hematology top 10%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
-
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
-
- RNA modifications and cancer 3
- RNA Interference and Gene Delivery 2
-
- Acute Myeloid Leukemia Research 4
- Hematopoietic Stem Cell Transplantation 2
- Co-authors
- David T. Scadden (12 shared papers)David Mooney (3 shared papers)Nisarg J. Shah (3 shared papers)Angelo S. Mao (3 shared papers)Ting‐Yu Shih (3 shared papers)Alexander J. Najibi (2 shared papers)Nick van Gastel (6 shared papers)Wei Zhong Leong (3 shared papers)
- Journals
- Blood (5 papers)Cell Metabolism (3 papers)Advanced Healthcare Materials (1 paper)Nature Biomedical Engineering (1 paper)Nature Biotechnology (1 paper)
- Partner nations
- United StatesSwedenChina
In The Last Decade
Azeem Sharda
12 papers receiving 388 citations
Peers
Comparison fields: 5 of 71
- Hematology 79
- Immunology 133
- Cancer Research 71
- Oncology 84
- Molecular Biology 186
Countries citing papers authored by Azeem Sharda
This map shows the geographic impact of Azeem Sharda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Azeem Sharda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Azeem Sharda more than expected).
Fields of papers citing papers by Azeem Sharda
This network shows the impact of papers produced by Azeem Sharda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Azeem Sharda. The network helps show where Azeem Sharda may publish in the future.
Co-authors
The 25 scholars most cited alongside Azeem Sharda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 103 | |
| 2 | 2020 | 102 | |
| 3 | 2019 | 89 | |
| 4 | 2021 | 65 | |
| 5 | 2018 | 16 | |
| 6 | 2025 | 8 | |
| 7 | 2020 | 3 | |
| 8 | 2017 | 2 | |
| 9 | 2024 | 2 | |
| 10 | 2019 | 1 | |
| 11 | 2021 | 1 | |
| 12 | 2022 | 1 | |
| 13 | 2026 | 0 | |
| 14 | 2025 | 0 |
About Azeem Sharda
Azeem Sharda is a scholar working on Molecular Biology, Hematology, Cancer Research, Immunology and Oncology, having authored 14 papers that have together received 393 indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (5 papers), Acute Myeloid Leukemia Research (4 papers), Immunotherapy and Immune Responses (3 papers), RNA modifications and cancer (3 papers), CAR-T cell therapy research (2 papers), Metabolism and Genetic Disorders (2 papers), Hematopoietic Stem Cell Transplantation (2 papers) and RNA Interference and Gene Delivery (2 papers). The work is most often cited by research in Hematology (79 citations), Immunology (133 citations), Cancer Research (71 citations), Oncology (84 citations) and Molecular Biology (186 citations). Azeem Sharda has collaborated with scholars based in United States, Sweden and China. Frequent co-authors include David T. Scadden, David Mooney, Nisarg J. Shah, Angelo S. Mao, Ting‐Yu Shih, Alexander J. Najibi, Nick van Gastel, Wei Zhong Leong, Sunia A. Trauger and Charles Vidoudez. Their work appears in journals such as Blood, Cell Metabolism, Advanced Healthcare Materials, Nature Biomedical Engineering and Nature Biotechnology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.